<DOC>
	<DOCNO>NCT01773070</DOCNO>
	<brief_summary>A follow study design obtain long term data subject either achieve sustain virologic response achieve sustain virologic response Abbott sponsor hepatitis C study .</brief_summary>
	<brief_title>A Follow Study Designed Obtain Long Term Data Subjects Who Either Achieved Sustained Virologic Response Did Not Achieve Sustained Virologic Response Abbott Sponsored Hepatitis C Study</brief_title>
	<detailed_description>A follow-up study ass resistance durability response three experimental drug ABT-450/r , ABT-267 , ABT-333 subject participate Phase 2 3 clinical study agent treatment chronic hepatitis C. The primary purpose study assess durability treatment response assess drug resistance .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>Subject receive least one dose ABT450 , ABT333 ABT267 prior Abbott HCV Phase 2 3 study submit US IND . The interval last dose Abbott DirectActing Antiviral Agent therapy previous clinical study enrollment Study M13102 must longer 2 year . The subject must voluntarily sign date inform consent form . Subject complete posttreatment period eligible prior study . The investigator considers subject unsuitable study reason . Receipt investigational product Day 1 enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Hepatitis C virus</keyword>
	<keyword>Direct Acting Antiviral</keyword>
	<keyword>Sustained Virologic Response</keyword>
	<keyword>Hepatitis C</keyword>
</DOC>